Inhibitory effect of caffeic acid phenethyl ester on mice bearing tumor involving angiostatic and apoptotic activities

• Published in: Chemico-biological interactions Vol. 186; no. 2; pp. 152 - 156
• Main Authors: El-Refaei, Mohamed F., El-Naa, Mona M.
• Format: Journal Article
• Language: English
• Published: Ireland Elsevier Ireland Ltd 30.07.2010
• Subjects: Animals; Anti-angiogenesis; Anti-tumor; Antineoplastic Agents - pharmacology; Apoptosis; Apoptosis - drug effects; Caffeic Acids - pharmacology; Carcinoma, Ehrlich Tumor - blood; Carcinoma, Ehrlich Tumor - blood supply; Carcinoma, Ehrlich Tumor - drug therapy; Carcinoma, Ehrlich Tumor - pathology; DNA fragmentation; DNA Fragmentation - drug effects; Endostatins - blood; Female; Humans; Matrix Metalloproteinase 9 - blood; Mice; Neovascularization, Pathologic - drug therapy; Phenylethyl Alcohol - analogs & derivatives; Phenylethyl Alcohol - pharmacology; Anti-tumor; Anti-angiogenesis; DNA fragmentation; Apoptosis
• ISSN: 0009-2797; 1872-7786
• DOI: 10.1016/j.cbi.2010.04.019

This study aims at investigating the anti-tumor effect of caffeic acid phenethyl ester (CAPE) against animal carcinogenesis. In order to substantiate this fact implanted tumor Ehrlich carcinoma cells were assessed in vivo to Swiss mice strain. We found that administrating of CAPE (15 mg/kg S.C.) showed that the tumor volume decreased significantly by 51%. As a result, it improved animal chances of survival and they became healthier. An anti-angiogenic effect of CAPE in vivo was observed, as determined by a significant serum matrix metalloproteinase (MMP-9) reduction (142.1 ng/ml), activation of endostatin serum level (1.9 ng/ml), as well as DNA fragmentation in tumor treated mice when compared with untreated ones. Conclusion: CAPE has a significant inhibitory effect on tumor in vivo. This inhibition may be related to its angiostatic and apoptotic effects. It also reduced angiogenic factors which may shift the equilibrium to the angiostatic effect of CAPE. These findings provide the possibility for the future use of CAPE as tumor therapy in human clinical trials.